Hormonal
Liver-derived extracellular vesicles (EVs) containing specific miRNAs (let-7e-5p, miR-210-3p, miR-31-5p) are secreted in response to lipid overload and directly target adipocytes to promote adipogenesis and lipogenesis, thereby remodeling adipose tissue.
This research highlights that liver health directly influences fat storage through biological signaling, not just caloric balance. While this doesn't provide a direct lifestyle fix, it suggests that improving liver metabolic health (e.g., reducing lipid overload) may naturally reduce the drive for adipose tissue expansion.
Here, we show that liver responds to lipid overload first and sends hepatocyte-derived extracellular vesicles (EVs) targeting adipocytes to regulate adipogenesis and lipogenesis.
Why this rating
Strong mechanistic evidence using mouse models, cell cultures, and human patient correlation (NAFLD), but lacks direct human interventional trials.
Source
Liver governs adipose remodelling via extracellular vesicles in response to lipid overload
Yue Zhao et al. · Nature Communications · 2020
DOI 10.1038/s41467-020-14450-6
More from this paper
- Geranylgeranyl diphosphate synthase (Ggpps) in the liver is required for the secretion of lipid-overload-responsive EVs; liver-specific deletion of Ggpps reduces adipose mass and improves glucose tolerance.Good
- Specific miRNAs (let-7e-5p, miR-210-3p) packaged in liver-derived EVs directly target Pgc1α in adipocytes to inhibit mitochondrial biogenesis and promote lipid accumulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →